ClinicalTrials.gg
Not yet recruitingNCT07608679PRE-COCOUpdated May 27, 2026

Estimation of the Prevalence of Microcirculatory Dysfunction in Uremic Cardiopathy Among Dialysis Patients

An interventional study of Transthoracic ultrasound at rest and Cardiological stress test in Hemodyalysis, sponsored by Centre Hospitalier Departemental Vendee. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Centre Hospitalier Departemental Vendee · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Patients with end-stage renal disease have a high burden of cardiovascular mortality, yet ischemic heart disease is often asymptomatic and difficult to diagnose in this population. Recent data suggest that microvascular coronary dysfunction may contribute significantly to myocardial ischemia in dialysis patients, but its true prevalence remains unknown. This study aims to evaluate microcirculatory coronary impairment in hemodialysis patients using invasive coronary angiography with measurement of coronary flow reserve (CFR), index of microcirculatory resistance (IMR). The study will also describe the clinical and biological characteristics associated with microvascular dysfunction in this population, in order to better understand the mechanisms of uremic cardiomyopathy and improve cardiovascular risk stratification.

02

Conditions studied

  • Hemodyalysis

Keywords

  • microcirculatory disorders
  • hemodyalysis
03

In context

Lead sponsor

Centre Hospitalier Departemental Vendee is the lead sponsor of 83 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients who have been on haemodialysis for at least 6 months
  • Elevated troponin levels > 40 ng/L in a sample taken whilst the patient was in a stable condition, dated within the last 3 months
  • Patients capable of understanding the protocol and who have given their written to participate in the research
  • Patients registered with the National Health Service or eligible for it

Exclusion criteria

Exclusion Criteria:

  • Age > 90 years
  • Patient undergoing daily home haemodialysis
  • Symptomatic stage 3 or 4 peripheral arterial disease
  • Severe hypertrophic cardiomyopathy (genetic or amyloid)
  • Severe valvular heart disease leading to left ventricular remodelling (surgically severe aortic stenosis, severe mitral regurgitation, severe aortic regurgitation)
  • Hospitalisation for decompensation/acute heart failure within the last month
  • Acute coronary syndrome and any coronary artery disease requiring angioplasty and/or stent implantation within the last 3 months
  • Contraindication to METHERGIN and DOBUTAMINE
  • Patients participating in another clinical research protocol that may affect the research objectives
  • Patients already included in the study
  • Patients under guardianship, curatorship or deprived of their liberty
  • Patients under an activated future protection order
  • Patients under family authorisation
  • Patient under judicial protection
  • Pregnant patient
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Interventions

  • Diagnostic testTransthoracic ultrasound at rest

    Transthoracic ultrasound at rest

  • Diagnostic testCardiological stress test

    Left to the discretion of the centre: dobutamine echocardiography or myocardial scintigraphy.

  • Diagnostic testCoronary angiography

    Even even if the stress test comes back normal (these tests appear to be less effective at diagnosing microcirculatory abnormalities)

06

What researchers measure

Primary outcomes

  1. Percentage of patients with microcirculatory heart disease (i.e. microvascular dysfunction or microvascular vasospasm) identified during coronary angiography

    Time frame: Cardiac examinations to be carried out within 8 to 10 weeks of enrolment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07608679
Lead sponsor
Centre Hospitalier Departemental Vendee
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Sep 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
May 27, 2026

Study contacts

Chloé MOREAU
Contact
promotion.urc@chd-vendee.fr
251446327 ext. +33
Grégoire COUVRAT-DESVERGNES
principal investigator · Centre Hospitalier Departemental Vendee

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion